Iscador
Iscador AG is a privately-held Swiss pharmaceutical company that develops and distributes ISCADOR®, a proprietary line of anthroposophical mistletoe preparations used by physicians and Heilpraktiker for integrative cancer treatment across Switzerland and Germany.
- Company typePrivate
- Founded1927
- HeadquartersLörrach, Germany
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Iscador does
Iscador AG is a privately-held Swiss pharmaceutical company (Aktiengesellschaft) headquartered in Arlesheim, Canton Basel-Country, Switzerland, specializing in anthroposophical mistletoe-based preparations for the integrative treatment of cancer. The company's single core product line, ISCADOR®, consists of Viscum album preparations offered in multiple varieties (M, Qu) and strengths (1mg, 2mg, 5mg), with some variants designated "spezifiziert" or "spezial," developed and manufactured at the Institut Hiscia in Arlesheim based on the pioneering research of Dr. Ita Wegman and Rudolf Steiner's anthroposophical medicine philosophy. The company traces its origins to 1927 and claims over 70 years of continuous operation at Institut Hiscia, marking a 100-year milestone in 2024.
The business operates a sales-led, professional-engagement go-to-market model targeting physicians, Heilpraktiker, and other integrative oncology practitioners, supported by a login-protected Professional Portal (Fachkreise), an active event presence (Heilpraktiker-Symposium, Charité Summerschool, Goetheanum Annual Conference, NATUM courses), company tours in Arlesheim, and a public "Leben mit Krebs" knowledge database for patients and relatives. Distribution occurs through Swiss pharmaceutical wholesalers into pharmacies for the home market and through authorized German distribution partners for Germany, with a dedicated shipping facility in Eimeldingen (DE) serving as the European dispatch point under Incoterms FCA Eimeldingen. Pricing is not publicly disclosed as products are prescription medicines routed through regulated pharmacy and partner channels.
Management comprises Sarah Monz and Björn Stehle as authorized representatives (Geschäftsleitung), Alexander Gutmans as Chairman of the Supervisory Board (Verwaltungssrat), Matthias Mütsch as Information Officer, and Kurt Engeloch as finance executive. No parent company, institutional investors, subsidiaries, or revenue figures are disclosed. In May 2026 the company announced the discontinuation of several ISCADOR® variants in Switzerland (spezifiziert 1/2/5 mg) and Germany (spezial 5 mg), available only until mid-2026 while supplies last, indicating a portfolio rationalization alongside continued operation of remaining strengths.
Iscador firmographics
Firmographics- Name
- Iscador
- Legal name
- Iscador AG
- Website
- https://iscador.com
- Company type
- Private
- Founded year
- 1927
- Operating status
- Operating
- Short description
- Iscador AG is a privately-held Swiss pharmaceutical company that develops and distributes ISCADOR®, a proprietary line of anthroposophical mistletoe preparations used by physicians and Heilpraktiker for integrative cancer treatment across Switzerland and Germany.
- Ownership category
- akta.pro rank
Iscador industry classification
Industry- Product category
- Anthroposophical Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
Keywords
Where Iscador is headquartered
LocationHeadquarters
- HQ city
- Lörrach
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Iscador business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Preparations Sales: Sale of proprietary mistletoe-based medicinal products (ISCADOR) in various strengths (1mg, 2mg, 5mg) for integrative cancer treatment, distributed through Swiss pharmacies and German distribution partners
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Iscador product offering
Product offeringCore offering
Iscador AG is a Swiss pharmaceutical company that manufactures and distributes anthroposophical mistletoe-based preparations (ISCADOR®) for the integrative treatment of cancer. Products are derived from Viscum album (mistletoe) and offered in varieties M and Qu at strengths of 1mg, 2mg, and 5mg, developed and produced at the Institut Hiscia based on the pioneering research of Dr. Ita Wegman and Rudolf Steiner. The company's offerings are prescription medicines distributed to medical professionals, pharmacies, and patients seeking holistic supportive cancer care.
Product overview
Iscador AG is a pharmaceutical company offering a single core product line, ISCADOR®, which consists of anthroposophic mistletoe preparations for integrative cancer treatment. The ISCADOR product family includes different varieties (M, Qu) in various strengths (1mg, 2mg, 5mg), with some variants designated as 'spezifiziert' (specified) or 'spezial' (special). The preparations are based on the research of physician Ita Wegman and the ideas of Rudolf Steiner, developed at the Institut Hiscia where they have been manufactured and distributed worldwide for over 70 years.
Differentiator
Problem solved
Functional benefit
Brands
- ISCADOR: Mistletoe-based pharmaceutical preparations for integrative cancer treatment
Products and services
- ISCADOR® Anthroposophic mistletoe (Viscum album) pharmaceutical preparation for integrative cancer treatment. Available in multiple varieties (M, Qu) — some specified as 'spezifiziert' or 'spezial' — and strengths of 1mg, 2mg, and 5mg. Prescribed by physicians and natural health practitioners (Heilpraktiker) for cancer patients seeking supportive oncology care and improved quality of life.
Companies that use Iscador
Customer profileSegments2 records
Ideal customer profiles2 records
Iscador technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Iscador partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Institut HisciacoreInstitut Hiscia is the research institution where Iscador AG's mistletoe preparations are developed and manufactured. This represents a core operational partnership for the company's primary products, with over 70 years of collaborative history in anthroposophical medicine research.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Iscador competitors and assessment
Company assessmentBroad incumbents
- Roche Holding AG: Leading Swiss-headquartered oncology pharmaceutical major with Basel-area operations; comparable as a mature Swiss specialty pharma operator with extensive oncology relationships, though its portfolio is dominated by targeted biologics rather than botanical preparations.
- Novartis AG: Swiss-headquartered global pharmaceutical major with substantial oncology franchise; provides a broad incumbent comparable on Swiss specialty pharma footprint, regulatory sophistication, and pharmacy channel access that dwarfs Iscador's scale.
Direct peers
- WALA Heilmittel GmbH: Anthroposophical pharmaceutical manufacturer with a broader portfolio of natural medicinal products including oncology-adjacent preparations, operating under the same Rudolf Steiner-based tradition as Iscador.
- Helixor Heilmittel GmbH & Co. KG: German pharmaceutical manufacturer of mistletoe preparations for cancer treatment, the most direct competitor to ISCADOR with overlapping oncology claims, prescriber base, and anthroposophical/complementary positioning.
- Abnoba GmbH: Producer of mistletoe (Viscum album) extracts for integrative oncology, offering comparable prescription-grade preparations that compete for the same prescriber and patient segment as Iscador.
- Weleda AG: Swiss-headquartered anthroposophical medicine company producing natural medicinal and body care products, sharing the anthroposophical heritage and overlapping distribution in pharmacies and specialized practitioners with Iscador.
Emerging players
- Bionorica SE: German phytopharmaceutical company producing plant-based prescription medicines for a range of indications; comparable to Iscador in business model (botanical-to-pharma) and DACH market focus, though not in oncology.
Regional players
- Schwabe Pharma AG: Swiss producer of plant-based (phytopharmaceutical) medicines with extensive pharmacy distribution in Switzerland; comparable to Iscador as a domestically distributed botanical pharmaceutical peer in the same regulatory and channel environment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Iscador social profiles
Digital presenceIscador financial estimates
Financial estimateRevenue estimate
Valuation estimate
Iscador leadership team
Management profileNumber of profiles
Profiles4 records
Iscador funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Iscador M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Iscador
What does Iscador do?
Iscador AG is a Swiss pharmaceutical company that manufactures and distributes anthroposophical mistletoe-based preparations (ISCADOR®) for the integrative treatment of cancer. Products are derived from Viscum album (mistletoe) and offered in varieties M and Qu at strengths of 1mg, 2mg, and 5mg, developed and produced at the Institut Hiscia based on the pioneering research of Dr. Ita Wegman and Rudolf Steiner. The company's offerings are prescription medicines distributed to medical professionals, pharmacies, and patients seeking holistic supportive cancer care.
Is Iscador a public or private company?
Iscador is a private company. It is classified as unknown and is currently operating.
When was Iscador founded?
Iscador was founded in 1927.
Where is Iscador based?
Iscador is headquartered in Lörrach, Germany, in the Europe region.
How does Iscador make money?
One revenue line is on record: pharmaceutical Preparations Sales.
Who are Iscador's main competitors?
Broad incumbents on record are Roche Holding AG and Novartis AG. Direct peers are WALA Heilmittel GmbH, Helixor Heilmittel GmbH & Co. KG, Abnoba GmbH and Weleda AG. Bionorica SE is listed as an emerging player. Schwabe Pharma AG is listed as a regional player.
Does Iscador have an API?
No public API is recorded for Iscador.
What industry is Iscador in?
Iscador's product category is Anthroposophical Pharmaceuticals. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology. Its NAICS code is 325411 and its SIC code is 2833.